Advanced basal cell carcinoma, the hedgehog pathway, and treatment options – role of smoothened inhibitors
Leslie A Fecher,1,3 William H Sharfman2 1Department of Internal Medicine and Dermatology, Indiana University Health Simon Cancer Center, Indianapolis, IN, USA; 2The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA, 3Department of Internal Medicine and Dermatology, Unive...
Guardado en:
Autores principales: | Fecher LA, Sharfman WH |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0a9e723d77f845c3a87150274d0be2a3 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Treatment of Advanced Basal Cell Carcinoma with Hedgehog Pathway Inhibitors: A Multidisciplinary Expert Meeting
por: Vincenzo De Giorgi, et al.
Publicado: (2021) -
Activation of the Hedgehog and Wnt/β-Catenin Signaling Pathways in Basal Cell Carcinoma
por: Tomoaki Takada
Publicado: (2021) -
Nonsurgical Options for the Treatment of Basal Cell Carcinoma
por: John Paoli, et al.
Publicado: (2019) -
Hedgehog Pathway Inhibitors against Tumor Microenvironment
por: Silpa Gampala, et al.
Publicado: (2021) -
Evaluation of Hedgehog Pathway Inhibition on Nevoid Basal Cell Carcinoma Syndrome Fibroblasts and Basal Cell Carcinoma-Associated Fibroblasts: Are Vismodegib and Sonidegib Useful to Target Cancer-Prone Fibroblasts?
por: Laura Eibenschutz, et al.
Publicado: (2021)